Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Invested Capital (2016 - 2025)

Arrowhead Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $608.4 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 954.46% year-over-year to $608.4 million; the TTM value through Dec 2025 reached $608.4 million, up 954.46%, while the annual FY2025 figure was $543.4 million, 184.42% up from the prior year.
  • Invested Capital reached $608.4 million in Q4 2025 per ARWR's latest filing, up from $543.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $749.2 million in Q1 2025 to a low of $57.7 million in Q4 2024.
  • Average Invested Capital over 5 years is $413.0 million, with a median of $427.6 million recorded in 2021.
  • Peak YoY movement for Invested Capital: plummeted 66.78% in 2024, then soared 954.46% in 2025.
  • A 5-year view of Invested Capital shows it stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then crashed by 56.17% to $173.7 million in 2023, then tumbled by 66.78% to $57.7 million in 2024, then skyrocketed by 954.46% to $608.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Invested Capital are $608.4 million (Q4 2025), $543.4 million (Q3 2025), and $562.3 million (Q2 2025).